Combination of cyclosporine a with corticosteroids is effective for the treatment of neuromyelitis optica

Journal of Neurology

Volumn 260, Issue 2, 2013, Pages 627-634

  Kageyama, Takashi ^a   Komori, Mika ^b   Miyamoto, Katsuichi ^c   Ozaki, Akihiko ^d   Suenaga, Toshihiko ^a   Takahashi, Ryosuke ^b   Kusunoki, Susumu ^c   Matsumoto, Sadayuki ^d   Kondo, Takayuki ^d,e  

^a TENRI HOSPITAL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Kitano Hospital   (Japan)

^e Takeda Hospital   (Japan)

Author keywords

Anti aquaporin 4 antibody; Azathioprine; Cyclosporine A; Neuromyelitis optica

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MIZORIBINE; PREDNISONE; TACROLIMUS;

ADULT; AGED; ARTICLE; CORTICOSTEROID THERAPY; DISABILITY SEVERITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES; AQUAPORIN 4; AZATHIOPRINE; CYCLOSPORINE; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; TREATMENT OUTCOME;

EID: 84878889954     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6692-2     Document Type: Article

References (36)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805-815
2. Watanabe S, Misu T, Miyazawa I et al (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13:968-974
3. Costanzi C, Matiello M, Lucchinetti CF et al (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77:659-666
4. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA (2010) Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 67:1131-1136
5. Mok CC, To CH, Mak A, Poon WL (2008) Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 35:172-174
6. Chia WC, Wang JN, Lai MC (2010) Neuromyelitis optica: a case report. Pediatr Neonatol 51:347-352
7. Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, Bakshi R (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63:957-963
8. Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ (2011) Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 68:473-479
9. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66:1128-1133
10. Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443-1448
11. Pellkofer HL, Krumbholz M, Berthele A et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76:1310-1315
12. Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651-662
13. Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS (2012) Variable results after rituximab in neuromyelitis optica. J Neurol Sci 317:103-105
14. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485-1489
15. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
16. Rodrigo E, Ruiz JC, Angeles de Cos M et al (2009) Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation. Transplant Proc 41:2328-2331
17. Hangler HB, Ruttmann E, Geltner C et al (2008) Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation. Clin Transplant 22:35-40
18. Germano V, Picchianti Diamanti A, Ferlito C et al (2011) Cyclosporine A in the long-term management of systemic lupus erythematosus. J Biol Regul Homeost Agents 25:397-403
19. Kotani T, Takeuchi T, Makino S et al (2011) Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 30:1021-1028
20. Griveas I, Visvardis G, Papadopoulou D et al (2010) Effect of cyclosporine therapy with low doses of corticosteroids on idiopathic nephrotic syndrome. Artif Organs 34:234-237
21. Utsugisawa K, Nagane Y, Suzuki S, Suzuki N (2008) Monitoring treatment with cyclosporine microemulsion in myasthenia gravis. Eur J Neurol 15:598-604
22. Odaka M, Tatsumoto M, Susuki K, Hirata K, Yuki N (2005) Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry 76:1115-1120
23. Takeuchi A, Shirai S, Horiuchi K et al (2012) Successful cyclosporine treatment in 2 patients with refractory CIDP, involving monitoring of both AUC(0-4 h) and trough levels. Rinsho Shinkeigaku 52:172-177
24. Arai M (2009) Relapsing transverse myelitis with anti-aquaporin 4 seropositivity: possible beneficial effects of ciclosporin. Rinsho Shinkeigaku 49:48-51
25. Heidt S, Roelen DL, Eijsink C et al (2009) Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol 159:199-207
26. Tsuda K, Yamanaka K, Kitagawa H et al (2012) Calcineurin inhibitors suppress cytokine production from memory t cells and differentiation of naive T cells into cytokine-producing mature T cells. PLoS One 7:e31465
27. Lucchinetti CF, Mandler RN, McGavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125:1450-1461
28. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473-477
29. Kira J (2011) Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders. J Neurol Sci 311:69-77
30. Matsuya N, Komori M, Nomura K et al (2011) Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int Immunol 23:565-573
31. Uzawa A, Mori M, Ito M et al (2009) Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 256:2082-2084
32. Içöz S, Tüzün E, Kürtüncü M et al (2010) Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 120:71-75
33. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T (2012) Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. doi: 10.1007/s10165-012-0715-9
34. Bennett JL, Lam C, Kalluri SR et al (2009) Intrathecal pathogenic antiaquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66:617-629
35. Bradl M, Misu T, Takahashi T et al (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630-643
36. Pohl M, Fischer MT, Mader S et al (2011) Pathogenic T cell responses against aquaporin 4. Acta Neuropathol 122:21-34